FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007998775> ?p ?o ?g. }

• W2007998775 abstract "The erythropoiesis-stimulating agents epoetin alfa (EPO) and darbepoetin alfa (DPO) effectively treat the anemia that occurs in most patients undergoing hemodialysis. Published studies indicate that these 2 agents have similar efficacy and safety outcomes, but their relative costs in actual practice in Canada have not been extensively studied.To determine the relative utilization and cost of erythropoiesis-stimulating agents in Canadian practice. Secondary objectives were to examine various clinical parameters in patients receiving these drugs.In this retrospective, open-label, observational study, 3 hospital-based hemodialysis centres in Ontario, Canada, converted patients from EPO to DPO over the period July 2004 to April 2006. The starting dose-conversion ratio was 200:1. The dose of DPO was changed, as needed, to achieve the same target hemoglobin (Hb) as before the conversion (110-120 g/L). For 3 to 6 months before conversion, and for 6 to 12 months after, weekly dose of erythropoiesis-stimulating agent, dose-conversion ratio, serum Hb, ferritin, and transferrin saturation were recorded for each patient at all 3 sites. One site also documented medication administration errors before and after the conversion.Data were collected for a total of 442 patients. Baseline patient characteristics were similar across the 3 sites. The median dose-conversion ratio for each hemodialysis centre ranged from 288:1 to 400:1, and the average annual per-patient savings varied between $2140 and $4711. No clinically meaningful differences between EPO and DPO were reported in terms of patients' serum hemoglobin levels, iron dose, or number of transfusions. With DPO, the relative risk of medication administration errors was reduced by 72% (p < 0.001) (based on data from one site).In this real-world evaluation of the clinical effectiveness and cost-efficiency of switching patients from EPO to DPO, patients' clinical outcomes were maintained while considerable reductions in cost were achieved." @default.
• W2007998775 created "2016-06-24" @default.
• W2007998775 creator A5001522854 @default.
• W2007998775 creator A5046542567 @default.
• W2007998775 creator A5049823064 @default.
• W2007998775 creator A5079286178 @default.
• W2007998775 creator A5079669974 @default.
• W2007998775 date "2012-12-10" @default.
• W2007998775 modified "2023-10-01" @default.
• W2007998775 title "Conversion from Epoetin Alfa to Darbepoetin Alfa: Effects on Patients’ Hemoglobin and Costs to Canadian Dialysis Centres" @default.
• W2007998775 cites W2004714428 @default.
• W2007998775 cites W2010937036 @default.
• W2007998775 cites W2043052921 @default.
• W2007998775 cites W2059698794 @default.
• W2007998775 cites W2108582978 @default.
• W2007998775 cites W2119363129 @default.
• W2007998775 cites W2134487085 @default.
• W2007998775 cites W2312781834 @default.
• W2007998775 cites W95049917 @default.
• W2007998775 doi "https://doi.org/10.4212/cjhp.v65i6.1192" @default.
• W2007998775 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3517789" @default.
• W2007998775 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23288954" @default.
• W2007998775 hasPublicationYear "2012" @default.
• W2007998775 type Work @default.
• W2007998775 sameAs 2007998775 @default.
• W2007998775 citedByCount "6" @default.
• W2007998775 countsByYear W20079987752015 @default.
• W2007998775 countsByYear W20079987752017 @default.
• W2007998775 countsByYear W20079987752021 @default.
• W2007998775 countsByYear W20079987752022 @default.
• W2007998775 crossrefType "journal-article" @default.
• W2007998775 hasAuthorship W2007998775A5001522854 @default.
• W2007998775 hasAuthorship W2007998775A5046542567 @default.
• W2007998775 hasAuthorship W2007998775A5049823064 @default.
• W2007998775 hasAuthorship W2007998775A5079286178 @default.
• W2007998775 hasAuthorship W2007998775A5079669974 @default.
• W2007998775 hasBestOaLocation W20079987751 @default.
• W2007998775 hasConcept C126322002 @default.
• W2007998775 hasConcept C153852466 @default.
• W2007998775 hasConcept C2776164570 @default.
• W2007998775 hasConcept C2777417653 @default.
• W2007998775 hasConcept C2778063415 @default.
• W2007998775 hasConcept C2778248108 @default.
• W2007998775 hasConcept C2778319317 @default.
• W2007998775 hasConcept C2778534260 @default.
• W2007998775 hasConcept C2778917026 @default.
• W2007998775 hasConcept C2779703530 @default.
• W2007998775 hasConcept C2779978075 @default.
• W2007998775 hasConcept C2781404941 @default.
• W2007998775 hasConcept C71924100 @default.
• W2007998775 hasConceptScore W2007998775C126322002 @default.
• W2007998775 hasConceptScore W2007998775C153852466 @default.
• W2007998775 hasConceptScore W2007998775C2776164570 @default.
• W2007998775 hasConceptScore W2007998775C2777417653 @default.
• W2007998775 hasConceptScore W2007998775C2778063415 @default.
• W2007998775 hasConceptScore W2007998775C2778248108 @default.
• W2007998775 hasConceptScore W2007998775C2778319317 @default.
• W2007998775 hasConceptScore W2007998775C2778534260 @default.
• W2007998775 hasConceptScore W2007998775C2778917026 @default.
• W2007998775 hasConceptScore W2007998775C2779703530 @default.
• W2007998775 hasConceptScore W2007998775C2779978075 @default.
• W2007998775 hasConceptScore W2007998775C2781404941 @default.
• W2007998775 hasConceptScore W2007998775C71924100 @default.
• W2007998775 hasLocation W20079987751 @default.
• W2007998775 hasLocation W20079987752 @default.
• W2007998775 hasLocation W20079987753 @default.
• W2007998775 hasOpenAccess W2007998775 @default.
• W2007998775 hasPrimaryLocation W20079987751 @default.
• W2007998775 isParatext "false" @default.
• W2007998775 isRetracted "false" @default.
• W2007998775 magId "2007998775" @default.
• W2007998775 workType "article" @default.